Search
Resiniferatoxin
go.drugbank.com/drugs/DB06515InvestigationalResiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission
Carthamus tinctorius flower bud
go.drugbank.com/drugs/DB14278ApprovedCarthamus tinctorius flower bud is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Zanthoxylum clava-herculis whole
go.drugbank.com/drugs/DB14353ApprovedZanthoxylum clava-herculis whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Pexelizumab
go.drugbank.com/drugs/DB04949InvestigationalPexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug. It is being investigated by Alexion Pharmaceuticals.
Ethoheptazine
go.drugbank.com/drugs/DB08988ApprovedWithdrawnEthoheptazine is marketed under the name Zactane. It is a phenazepine based opioid analgesic. It was invented in the 1950s and is related to other drugs such as proheptazine. … Ethoheptazine is no longer marketed in the United States.
ALKS 29
go.drugbank.com/drugs/DB05723ExperimentalALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.
IDD-1
go.drugbank.com/drugs/DB05439ExperimentalEladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.
Imdatifan
go.drugbank.com/drugs/DB21643ExperimentalImdatifan is a small molecule drug. The usage of the INN stem '-tifan' in the name indicates that Imdatifan is a hypoxia inducible factor (HIF)-2alpha (HIF-2a) inhibitor. … Imdatifan has a monoisotopic molecular weight of 385.05 Da.
Veltuzumab
go.drugbank.com/drugs/DB05656InvestigationalVeltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
HY10275
go.drugbank.com/drugs/DB05079ExperimentalHY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. … HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep.